Experience
Federal Circuit win for Eli Lilly’s Xigris®, a recombinant form of human Activated Protein
Ariad Pharmaceuticals
Eli Lilly and Company
Finnegan successfully represented Eli Lilly in connection with a lawsuit brought by Ariad Pharmaceuticals, accusing Lilly’s Xigris® product of infringing Ariad’s patent covering “NF-κB” technology. After a full en banc hearing, the U.S. Court of Appeals for the Federal Circuit held Ariad’s patent invalid under 35 U.S.C. § 112 for failing to comply with the written description requirement.
Ariad Pharmaceuticals v. Eli Lilly and Company, 08-1248, Fed. Cir., Judges Michel, Newman, Mayer, Lourie, Rader, Bryson, Gajarsa, Linn, Dyk, Prost, Moore
Ariad Pharmaceuticals v. Eli Lilly and Company, 1:02-cv-11280, D. Mass., Judge Zobel
